Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long?

Journal of Allergy and Clinical Immunology

Volumn 136, Issue 5, 2015, Pages 1407-1409

  Barmettler, Sara ^a   Price, Christina ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; RITUXIMAB; IMMUNOGLOBULIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; B LYMPHOCYTE SUBPOPULATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; GRANULOMATOSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; LYMPHOMA; MALE; MALIGNANT NEOPLASM; MEMORY CELL; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; YOUNG ADULT; ADOLESCENT; AGAMMAGLOBULINEMIA; CHEMICALLY INDUCED; CHILD; GENE REARRANGEMENT; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; MALE; MIDDLE AGED; RITUXIMAB; YOUNG ADULT;

EID: 85027929755     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.06.035     Document Type: Article

References (9)

1. Buch, M.H., Smolen, J.S., Betteridge, N., Breedveld, F.C., Burmester, G., Dörner, T., et al., for the Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 909–920.
2. Kimby, E., Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31 (2005), 456–473.
3. Cunningham-Rundles, C., Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 28 (2008), S42–S45.
4. Diwakar, L., Gorrie, S., Richter, A., Chapman, O., Dhillon, P., Al-Ghanmi, F., et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia?. J Clin Pathol 63 (2010), 275–277.
5. Makatsori, M., Kiani-Alikhan, S., Manson, A.L., Verma, N., Leandro, M., Gurugama, N.P., et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM 107 (2014), 821–828.
6. Casulo, C., Maragulia, J., Zelenetz, A.D., Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 13 (2013), 106–111.
7. Roberts, D.M., Jones, R.B., Smith, R.M., Alberici, F., Kumaratne, D.S., Burns, S., et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun 57 (2015), 24–29.
8. Roll, P., Dörner, T., Tony, H.-P., Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 58 (2008), 1566–1575.
9. Cameron, P.U., Jones, P., Gorniak, M., Dunster, K., Paul, E., Lewin, S., et al. Splenectomy associated changes in IgM memory B cells in an adult spleen registry cohort. PLoS One, 6, 2011, e23164.